The Clinical Utility of Blood Derived Gene Cluster Analysis of Neuroendocrine Tumors Using Neoplasia Hallmark Criteria Abstract #1222

Introduction: We developed a multianalyte blood (51 transcript) assay (MAAA) for GEP-NETs with a sensitivity (98%) and specificity (97%).
Aim(s): Examine tissue expression levels to define, by cluster analysis, the biological “hallmarks” of NET neoplasia and clinical utility.
Materials and methods: Group 1: Expression in 2 NET transcriptome databases ( n=15) assessed by GeneProfiler and by PCR (tissue with matched blood: n=24). Group 2 (n=138): stable disease (SD): n=94; progressive disease (PD): n=44. Validation Groups: surgical resection (n=27) and SSA treatment (n=35). Regulatory network analysis, PCA, and ROC were used to delineate and evaluate neoplasia “hallmarks”.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
#316 Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia
Introduction: Despite an increasing incidence, a paucity of biological information has led to major limitations in identification of plausible therapeutic targets for small intestinal neuroendocrine tumors (SINETs)
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms
Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, ...
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR